Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Ragothaman Srinivasan

ALX Oncology Shares Soar As FDA Grants Orphan Drug Status To Blood Cancer Candidate

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ALX Oncology Holdings’ (NASDAQ:ALXO) Evorpacept for the treatment of patients with acute myeloid leukemia (AML).

Evorpacept in combination with venetoclax and azacitidine is being evaluated in the Phase 1/2 ASPEN-05 study in patients with previously untreated AML who are not candidates for intensive induction therapy or with relapsed/refractory AML.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.